An Anaplastic Lymphoma Kinase-positive Inflammatory Myofibroblastic Tumor with Rapidly Acquired Resistance to First-line Anaplastic Lymphoma Kinase Inhibitor: A Case and Literature Review
Inflammatory myofibroblastic tumors (IMTs) are soft-tissue neoplasms with rare metastatic potential. Approximately half of IMTs are positive for an anaplastic lymphoma kinase (ALK) gene rearrangement which causes aberrant expression. Early phase clinical trials have demonstrated the efficacy of ALK...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-01-01
|
| Series: | Journal of Cancer Research and Practice |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-23-00032 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591068054421504 |
|---|---|
| author | Shu-Cheng Wu Hsing-Wu Chen |
| author_facet | Shu-Cheng Wu Hsing-Wu Chen |
| author_sort | Shu-Cheng Wu |
| collection | DOAJ |
| description | Inflammatory myofibroblastic tumors (IMTs) are soft-tissue neoplasms with rare metastatic potential. Approximately half of IMTs are positive for an anaplastic lymphoma kinase (ALK) gene rearrangement which causes aberrant expression. Early phase clinical trials have demonstrated the efficacy of ALK inhibitors in the treatment of IMTs. However, there is no definite conclusion on which ALK inhibitor performs best, and data regarding subsequent therapy after first-line ALK inhibitor failure are scarce. Here, we report a case of ALK+ metastatic IMT that demonstrated a dramatic response to first-line alectinib but resulted in rapidly acquired resistance. Repeated biopsy and next-generation sequencing (NGS) showed ALK:c.3604G>A; p.(Gly1202Arg), which is a common mechanism of drug resistance in ALK fusion-positive non-small cell lung cancer. We also report subsequent treatment choices and responses in this patient and perform a literature review regarding similar cases as this rare tumor. |
| format | Article |
| id | doaj-art-eb03e0fa936e428c8bf0b086b4528d53 |
| institution | Kabale University |
| issn | 2311-3006 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Cancer Research and Practice |
| spelling | doaj-art-eb03e0fa936e428c8bf0b086b4528d532025-01-23T05:10:53ZengWolters Kluwer Medknow PublicationsJournal of Cancer Research and Practice2311-30062024-01-01111444810.4103/ejcrp.eJCRP-D-23-00032An Anaplastic Lymphoma Kinase-positive Inflammatory Myofibroblastic Tumor with Rapidly Acquired Resistance to First-line Anaplastic Lymphoma Kinase Inhibitor: A Case and Literature ReviewShu-Cheng WuHsing-Wu ChenInflammatory myofibroblastic tumors (IMTs) are soft-tissue neoplasms with rare metastatic potential. Approximately half of IMTs are positive for an anaplastic lymphoma kinase (ALK) gene rearrangement which causes aberrant expression. Early phase clinical trials have demonstrated the efficacy of ALK inhibitors in the treatment of IMTs. However, there is no definite conclusion on which ALK inhibitor performs best, and data regarding subsequent therapy after first-line ALK inhibitor failure are scarce. Here, we report a case of ALK+ metastatic IMT that demonstrated a dramatic response to first-line alectinib but resulted in rapidly acquired resistance. Repeated biopsy and next-generation sequencing (NGS) showed ALK:c.3604G>A; p.(Gly1202Arg), which is a common mechanism of drug resistance in ALK fusion-positive non-small cell lung cancer. We also report subsequent treatment choices and responses in this patient and perform a literature review regarding similar cases as this rare tumor.https://journals.lww.com/10.4103/ejcrp.eJCRP-D-23-00032anaplastic lymphoma kinase inhibitorinflammatory myofibroblastic tumorsarcoma |
| spellingShingle | Shu-Cheng Wu Hsing-Wu Chen An Anaplastic Lymphoma Kinase-positive Inflammatory Myofibroblastic Tumor with Rapidly Acquired Resistance to First-line Anaplastic Lymphoma Kinase Inhibitor: A Case and Literature Review Journal of Cancer Research and Practice anaplastic lymphoma kinase inhibitor inflammatory myofibroblastic tumor sarcoma |
| title | An Anaplastic Lymphoma Kinase-positive Inflammatory Myofibroblastic Tumor with Rapidly Acquired Resistance to First-line Anaplastic Lymphoma Kinase Inhibitor: A Case and Literature Review |
| title_full | An Anaplastic Lymphoma Kinase-positive Inflammatory Myofibroblastic Tumor with Rapidly Acquired Resistance to First-line Anaplastic Lymphoma Kinase Inhibitor: A Case and Literature Review |
| title_fullStr | An Anaplastic Lymphoma Kinase-positive Inflammatory Myofibroblastic Tumor with Rapidly Acquired Resistance to First-line Anaplastic Lymphoma Kinase Inhibitor: A Case and Literature Review |
| title_full_unstemmed | An Anaplastic Lymphoma Kinase-positive Inflammatory Myofibroblastic Tumor with Rapidly Acquired Resistance to First-line Anaplastic Lymphoma Kinase Inhibitor: A Case and Literature Review |
| title_short | An Anaplastic Lymphoma Kinase-positive Inflammatory Myofibroblastic Tumor with Rapidly Acquired Resistance to First-line Anaplastic Lymphoma Kinase Inhibitor: A Case and Literature Review |
| title_sort | anaplastic lymphoma kinase positive inflammatory myofibroblastic tumor with rapidly acquired resistance to first line anaplastic lymphoma kinase inhibitor a case and literature review |
| topic | anaplastic lymphoma kinase inhibitor inflammatory myofibroblastic tumor sarcoma |
| url | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-23-00032 |
| work_keys_str_mv | AT shuchengwu ananaplasticlymphomakinasepositiveinflammatorymyofibroblastictumorwithrapidlyacquiredresistancetofirstlineanaplasticlymphomakinaseinhibitoracaseandliteraturereview AT hsingwuchen ananaplasticlymphomakinasepositiveinflammatorymyofibroblastictumorwithrapidlyacquiredresistancetofirstlineanaplasticlymphomakinaseinhibitoracaseandliteraturereview AT shuchengwu anaplasticlymphomakinasepositiveinflammatorymyofibroblastictumorwithrapidlyacquiredresistancetofirstlineanaplasticlymphomakinaseinhibitoracaseandliteraturereview AT hsingwuchen anaplasticlymphomakinasepositiveinflammatorymyofibroblastictumorwithrapidlyacquiredresistancetofirstlineanaplasticlymphomakinaseinhibitoracaseandliteraturereview |